Brivaracetam(UCB-34714)|cas 357336-20-0|DC Chemicals

Cas No.:	357336-20-0
Chemical Name:	Brivaracetam
Synonyms:	1-Pyrrolidineacetamide,a-ethyl-2-oxo-4-propyl-, (aS,4R)-;Brivaracetam;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;Rikelta;UCB 34714;UCB-34714;(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;BRIVARACETAM [ORANGE BOOK];BRIVARACETAM (MART.);SCHEMBL122081;BRIVARACETAM [MART.];Brivaracetam [USAN:INN];1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; Brivaracetam; Briviact; UCB 34714;(2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE;AKOS027324306;Briviact;GTPL9041;DB05541;AC-29289;D08879;1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-;NS00068020;357336-20-0;AS-35277;UNII-U863JGG2IA;AE5 - Anti-epileptic drugs 5;BDBM50422531;NCGC00390779-02;CHEMBL607400;BB161996;1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-;BRIVARACETAM [JAN];(2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide;BRIVARACETAM [MI];BRIVARACETAM [INN];brivaracetamum;2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide;MSYKRHVOOPPJKU-BDAKNGLRSA-N;(2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;CS-3418;(S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide;CCG-266666;BRIVARACETAM [USAN];MFCD25976668;Briviact (TN);EX-A2748;U863JGG2IA;CHEBI:133013;DTXSID00905081;N03AX23;Q408099;(2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide;1-PYRROLIDINEACETAMIDE, alpha-ETHYL-2-OXO-4-PROPYL (alphaS,4R)-;HY-14449;BRIVARACETAM [WHO-DD];Brivaracetam (JAN/USAN/INN);compound 83alpha;UCB34714
SMILES:	CCC[C@@H]1CC(N([C@H](C(N)=O)CC)C1)=O
Formula:	C₁₁H₂₀N₂O₂
M.Wt:	212.2887
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Brivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels. in vitro: Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program. It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract. Carcinogenicity studies are ongoing. Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability. CSD episodes were regularly elicited on slices upon delivery of calibrated KCl drops and were recorded via two micropipette electrodes. After control CSDs, the drug was added to the perfusion and five subsequent CSDs were elicited during drug perfusion. Effects were assessed via CSD amplitude (Ampl) and duration at half-amplitude (D(1/2)). BRV, 10 and 32 microM reduced the Ampl and transiently the D(1/2). Levetiracetam, 32 and 100 microM had no effect on either Ampl or D(1/2). Brivaracetam bound selectively with 20 fold higher affinity than levetiracetam to SV2A. BRV produced a concentration-dependent inhibition of voltage-dependent Na(+) currents with IC(50) values of 41microM at the holding potential of -100mV, and of 6.5microM at the holding potential of -60mV. in vivo: BRV (2.1, 6.8 or 21.0mg/kg i.p.) was injected daily, 60min before each session. Results indicated that in both normal and amygdala-kindled rats BRV did not alter the latency to find the hidden platform or swimming speed during the four consecutive days of learning. brivaracetam (0.3 mg/kg, the minimal effective dose) was more potent than levetiracetam (3 mg/kg, the minimal effective dose) against post-hypoxic seizures.The anti-seizure activity of both compounds occurred 30 min following intraperitoneal (i.p.) administration and was maintained over the entire 150 min post-dose observation period. Both brivaracetam and levetiracetam significantly reduced auditory stimulated post-hypoxic myoclonus from a dose 0.3 mg/kg.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC70000	Lysyllysyllysine	Lysyllysyllysine is a cationic moietie that may be used in the construction of gene delivery vectors and DNA nanoparticles.
DC33580	DODMA	DODMA, also known as MBN 305A is a a cationic lipid containing the unsaturated long-chain (18:1) oleic acid inserted at both the sn-1 and sn-2 positions. It has been used in the composition of lipospomes formulated as stable nucleic acid lipid particles that can encapsulate siRNA or other small molecules to be used for drug delivery
DC33636	DOTAP	DOTAP, also known as 1,2-Dioleoyl-3-trimethylammoniumpropane, is a cationic liposome-forming compound used for transfection of DNA, RNA, and other negatively charged molecules into eukaryotic cells. It has been used in gene delivery vectors for gene ther
DC46471	RP101988	RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.
DC45184	Hydrofurimazine	Hydrofurimazine is a NanoLuc substrate whose enhanced aqueous solubility allows delivery of higher doses to mice. Hydrofurimazine enables sensitive bioluminescence imaging for either prolonged light production of high sensitivity.
DC37901	PD-173212	PD-173212 is a small molecule N-type calcium channel blocker.
DC37333	N,N-Diethyl-p-toluamide	N,N-Diethyl-p-toluamide is a mosquito repellent.
DC37321	AI3-15902	AI3-15902 is a biochemical.
DC37283	Methyl phenylcarbamate	Methyl phenylcarbamate is a biochemical.
DC37252	Ampyrone	Ampyrone is a metabolite of AMINOPYRINE with analgesic and anti-inflammatory properties. It is used as a reagent for biochemical reactions producing peroxides or phenols. Ampyrone stimulates LIVER MICROSOMES and is also used to measure extracellular water.